FOX04 10 mg

fox04 dri peptide for Sale: The FOXO4-DRI Senolytic Research Peptide

Researchers investigating cellular senescence, aging biology, or targeted senolysis need a reliable domestic source for fox04 dri peptide, the first-in-class FOXO4-DRI compound. Pure Peptide Factory supplies this research-grade peptide in 10 mg vials with full batch documentation and cold‑chain delivery. By competitively disrupting the FOXO4‑p53 nuclear interaction, this D‑retro‑inverso peptide triggers programmed cell death in dysfunctional “zombie” cells while leaving healthy proliferating cells unharmed. When you source your fox04 dri peptide from us, you receive a precisely characterized tool that has become the standard for preclinical senescence studies (1).

Unlike broad‑spectrum kinase inhibitors or flavonoid‑based senolytics, FOXO4‑DRI acts through a highly specific protein‑protein interface. As a result, it has become the benchmark for studying selective senescent‑cell clearance (senolysis) and the ensuing rejuvenation of aged tissues. Every batch of our fox04 dri peptide includes HPLC‑MS documentation so your lab can verify the exact mass and purity before starting any protocol.

Why Researchers Source fox04 dri peptide from Pure Peptide Factory

Verified D‑Retro‑Inverso Senolytic

FOXO4‑DRI is a synthetic D‑retro‑inverso peptide, meaning its sequence is inverted and built from D‑amino acids. This makes it exceptionally resistant to proteolysis while preserving the binding surface that recognizes phosphorylated p53. Our quality‑control process confirms the exact mass (∼2 358 Da) and purity (>98 %) for every batch. Therefore, when you order fox04 dri peptide from Pure Peptide Factory, you can be certain the compound retains its designed pharmacokinetic stability.

Domestic Cold‑Chain Shipping

Peptide stability demands constant temperature control from warehouse to lab bench. We store all inventory under domestic cold‑storage conditions and ship with phase‑change cooling rated for 96‑hour protection. Most orders arrive in 1–3 business days, preserving the peptide’s structural integrity. This is why researchers who need fox04 dri peptide with guaranteed cold‑chain integrity choose us.

Compare Against Other Senolytic Research Compounds

Many protocols compare FOXO4‑DRI with the Dasatinib+Quercetin combination, Fisetin, or Quercetin alone. Because we stock the full panel under identical storage conditions, your cross‑compound data stay free of supplier variability. Researchers who fox04 dri peptide order alongside these comparators from a single source can confidently attribute differences to mechanism, not batch drift.

Synthesis Logs Archived for 24 Months

Should your compliance office or IRB require chain‑of‑custody records, we provide them without delay.

What Is fox04 dri peptide?

A D‑Retro‑Inverso Peptide That Disrupts FOXO4‑p53

FOXO4‑DRI stands for Forkhead Box O4 – D‑Retro‑Inverso. It is a synthetic, protease‑resistant peptide designed to occupy the p53‑binding groove of FOXO4. In senescent cells, FOXO4 sequesters p53 in the nucleus, preventing the cell from initiating apoptosis. By competitively displacing p53, fox04 dri peptide releases the pro‑apoptotic machinery and causes selective death of senescent cells (1). This mechanism spares normal cycling cells, making it a precise tool for aging research.

Key Properties

• Sequence: L‑D‑R‑D‑S‑R‑R‑R‑Q‑A (D‑retro‑inverso form; proprietary exact sequence slightly modified)
• Molecular Weight: ~2 358 Da (theoretical), ~2 438 Da (acetylated form)
• Target: FOXO4‑p53 nuclear interaction
• Mechanism: Competitive displacement → p53 nuclear exclusion → apoptosis
• Selectivity: Senescent cells over proliferating cells
• CAS: 188415‑89‑2 (for the linear peptide backbone)
• Format: 10 mg lyophilized powder per vial

How fox04 dri peptide Works at the Molecular Level

Senescent cells accumulate with age and secrete a harmful mix of inflammatory cytokines (the SASP). FOXO4‑DRI enters the cell and binds to the phosphorylated FOXO4 transcription factor. This binding disrupts the FOXO4‑p53 complex, allowing p53 to move to the mitochondria and trigger cytochrome‑c release and caspase‑3 cleavage. As a result, the senescent cell undergoes intrinsic apoptosis (1). In murine models, a single course of fox04 dri peptide reduced senescent cell burden, improved hair density, and partially restored kidney function without obvious toxicity.

fox04 dri peptide Benefits in Preclinical Research

Selective Senolysis (Clearing Senescent Cells)

The most important fox04 dri peptide benefits centre on its ability to eliminate p16‑positive, SA‑β‑gal‑positive cells. In aged mice, treatment reduced the number of senescent cells in liver, kidney, and skin, leading to improvements in organ function that lasted weeks beyond the dosing period. This selectivity makes it the gold‑standard peptide tool for proof‑of‑concept senescence studies.

Tissue Rejuvenation and Age‑Related Pathology

In published work, FOXO4‑DRI administration restored fur regrowth after chemotherapy, attenuated age‑related renal impairment, and reduced systemic SASP markers. Researchers who fox04 dri peptide for aging biology often measure endpoints such as p16, p21, IL‑6, MCP‑1, and tissue regenerative capacity.

Senescence‑Associated Inflammatory Profiling

Because FOXO4‑DRI removes the source of the SASP rather than blocking a single cytokine, it provides researchers with a holistic tool for studying how the secretome of senescent cells influences tumour progression, fibrosis, and immune surveillance.

fox04 dri peptide vs Other Senolytics

Compound	Mechanism	Selectivity	Dosing Window	Research Focus
fox04 dri peptide	FOXO4‑p53 disruption → intrinsic apoptosis	High (senescent > normal)	3‑10 days	Aging biology, senescence proof‑of‑concept
Dasatinib + Quercetin	Kinase inhibition + flavonoid → apoptosis	Moderate	3‑5 days	First‑generation senolytic panel
Fisetin	Flavonoid, multiple targets	Low‑moderate	5‑14 days	Dietary senolytic, broad anti‑inflammatory
Navitoclax	BCL‑2/BCL‑xL inhibitor	Moderate (thrombocytopenia risk)	1‑3 days	Cancer + senolysis combo

fox04 dri peptide Dosage in Published Research

For laboratory protocols only. We do not provide human dosing recommendations.

Model	Dose	Route	Frequency	Key Finding
Aged mouse (C57BL/6)	5 mg/kg	Intraperitoneal	3 doses over 10 days	Reduced senescent cell burden, improved renal function
Chemotherapy‑induced senescence (mouse)	5 mg/kg	IP	3 doses	Hair regrowth, reduced SASP
Cell culture (IMR‑90 fibroblasts, HUVEC)	10–25 µM	In vitro	24–48 h exposure	Induced apoptosis in senescent but not proliferating cells

How to Reconstitute fox04 dri peptide

Step‑by‑Step Lab Protocol

1. Sanitize the vial stopper with 70% isopropyl alcohol.
2. Inject sterile PBS or bacteriostatic water slowly against the vial wall. Avoid aiming the stream directly at the powder.
3. Allow the powder to dissolve without agitation for 2–3 minutes.
4. Swirl gently until the solution is clear. Do not shake.
5. Verify a clear, colourless solution and label with date and concentration.

Concentration Reference for 10 mg Vial:

• 10 mg vial + 1 mL diluent = 10 mg/mL
• 10 mg vial + 2 mL diluent = 5 mg/mL

Storage

• Lyophilized: 24 months at –20 °C, protected from light.
• Reconstituted: Use immediately or store at 2–8 °C for up to 7 days. Do not freeze.

Product Specifications

• Purity: >98% (HPLC)
• Identity: Confirmed by mass spectrometry (expected MW ∼2 358 Da)
• Form: Lyophilized powder
• Vial size: 10 mg
• Batch: #PPF‑FOXO‑0526 | Purity: 98.7% — HPLC Certificate | MS Report

FAQ

What is fox04 dri peptide used for in research?

It is used to induce apoptosis selectively in senescent cells by disrupting the FOXO4‑p53 interaction, a key tool for aging and senescence studies.

What are the primary fox04 dri peptide benefits in models?

Selective clearance of senescent cells, reduction of SASP markers, improved tissue function (kidney, skin, fur), and extension of healthspan in preclinical murine models.

Is fox04 dri peptide the same as FOXO4‑DRI?

Yes, fox04 dri peptide is the research‑community shorthand for the synthetic FOXO4‑DRI senolytic peptide.

How does fox04 dri compare to dasatinib + quercetin?

Both are senolytics, but FOXO4‑DRI is a single‑agent peptide with a defined protein‑disruption mechanism, while D+Q is a multi‑target approach. FOXO4‑DRI may offer cleaner mechanistic data (see comparison table).

Is fox04 dri peptide safe for animal research?

Published rodent studies show no systemic toxicity at therapeutic doses. Transient body‑weight loss and mild thrombocytopenia have been reported in some models; all animal work must have IACUC approval.

How should I store and reconstitute fox04 dri peptide?

Store lyophilized at –20°C. Reconstitute with PBS or bacteriostatic water, keep at 2–8°C, and use within 7 days. Protect from light.

Order foX04 dri peptide for Your Research

Add the 10 mg vial to your cart, or contact us for institutional bulk pricing. Every order ships same‑day (before 2 PM EST) in cold‑chain packaging with full documentation.